Embr Wave for Hot Flashes
(ReduceHEAT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a prospective, randomized, non-pharmacologic interventional trial evaluating the effectiveness of the Embr Wave wearable thermal device in reducing hot flash burden in men with prostate cancer receiving androgen deprivation therapy (ADT). Participants will be randomized 1:1 to immediate (12 weeks) versus delayed (after 6 weeks) use of the Embr Wave device. The study aims to determine whether the device reduces vasomotor symptoms using a number of patient-reported outcomes
Who Is on the Research Team?
Daniel Sentana Lledo, MD
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
This trial is for men aged 18 or older with prostate cancer who are on hormone therapy (ADT) and have bothersome hot flashes (at least 28 per week). Participants must be able to consent, in good enough health to participate, and willing to stay on their current treatment during the study.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Embr Wave
Trial Overview
The study tests whether a wearable device called Embr Wave can help reduce hot flashes caused by hormone therapy in prostate cancer patients. Participants are randomly assigned to start using the device right away or after six weeks, over a total of twelve weeks.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants receive the Embr Wave device at the start of the study and use it for 12 weeks.
Participants receive usual care for the first 6 weeks, then receive the Embr Wave device for the next 6 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.